Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSCW) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to -$3.7 million.

  • Ensysce Biosciences' Net Income towards Common Stockholders fell 66350.9% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 million, marking a year-over-year decrease of 3841.73%. This contributed to the annual value of -$8.0 million for FY2024, which is 2483.33% up from last year.
  • Per Ensysce Biosciences' latest filing, its Net Income towards Common Stockholders stood at -$3.7 million for Q3 2025, which was down 66350.9% from -$1.7 million recorded in Q2 2025.
  • Ensysce Biosciences' Net Income towards Common Stockholders' 5-year high stood at $661769.0 during Q3 2024, with a 5-year trough of -$17.2 million in Q3 2021.
  • Its 5-year average for Net Income towards Common Stockholders is -$4.3 million, with a median of -$2.7 million in 2023.
  • As far as peak fluctuations go, Ensysce Biosciences' Net Income towards Common Stockholders tumbled by 516556.23% in 2021, and later soared by 12460.5% in 2024.
  • Over the past 5 years, Ensysce Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$10.8 million in 2021, then surged by 49.06% to -$5.5 million in 2022, then skyrocketed by 36.54% to -$3.5 million in 2023, then dropped by 1.72% to -$3.6 million in 2024, then dropped by 4.62% to -$3.7 million in 2025.
  • Its Net Income towards Common Stockholders was -$3.7 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$1.9 million in Q1 2025.